| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Common Stock | Tax liability | $842,430 | -19,878 | -11% | $42.38 | 161,535 | 22 Feb 2023 | Direct | F1 |
| holding | PFE | Common Stock | 1,739 | 22 Feb 2023 | By Rule 16b-3 Plan |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +80,360 | $0.000000 | 80,360 | 23 Feb 2023 | Common Stock | 80,360 | $42.30 | Direct | F2 | |
| transaction | PFE | Stock Appreciation Rights | Award | $0 | +69,938 | $0.000000 | 69,938 | 23 Feb 2023 | Common Stock | 69,938 | $42.30 | Direct | F3 |
| Id | Content |
|---|---|
| F1 | The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the settlement of stock units from previously exercised stock appreciation rights (including dividend equivalents thereon). |
| F2 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. |
| F3 | The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. |